Clinical Trial

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-11; most recent amendment 2026-02-23.
Status change: Recruiting → Not Yet Recruiting 2025-07-07
Status change: Not Yet Recruiting → Recruiting 2023-07-30
Trial Details
NCT Number NCT05909488
Lead Sponsor PT. Prodia Stem Cell Indonesia
Conditions Retinitis Pigmentosa
Enrollment 30 participants
Start Date 2026-05
Primary Completion 2027-07 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-25